Meyler's Side Effects of Endocrine and Metabolic Drugs (eBook)
708 Seiten
Elsevier Science (Verlag)
978-0-08-093292-7 (ISBN)
Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician.
Endocrine and metabolic diseases are common, includes diseases such as diabetes, thyroid disease, and obesity. Endocrinologists, including diabetes professionals, internal medicine and primary care practitioners, obstetricians and gynecologists, and others will find this book useful when treating endocrine or metabolic diseases.
The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler's Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN), when those are not available, clinical names have been used. In some cases, brand names have been used.
This volume is critical for any health professional involved in the administration of endocrine and metabolics mediations.
-
- Surpasses the Physician's Desk Reference ? by including clinical case studies and independent expert analysis
- Complete index of drug names
- Most complete cross referencing of drug-drug interactions available
- Extensive references to primary and secondary literature
- Also includes information on adverse effects in pregnancy
The book is divided into eight sections:
- Corticosteroids and related drugs
- Prostaglandins
- Sex hormones and related drugs
- Iodine and drugs that affect thyroid function
- Insulin and other hypoglycemic drugs
- Other hormones and related drugs
- Lipid-regulated drugs
- Endocrine and metabolic adverse effects of non-hormonal and non-metabolic drugs
Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. Endocrine and metabolic diseases are common, includes diseases such as diabetes, thyroid disease, and obesity. Endocrinologists, including diabetes professionals, internal medicine and primary care practitioners, obstetricians and gynecologists, and others will find this book useful when treating endocrine or metabolic diseases.The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler's Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.This volume is critical for any health professional involved in the administration of endocrine and metabolics mediations. -- Surpasses the Physician's Desk Reference by including clinical case studies and independent expert analysis- Complete index of drug names- Most complete cross referencing of drug-drug interactions available- Extensive references to primary and secondary literature- Also includes information on adverse effects in pregnancy The book is divided into eight sections:- Corticosteroids and related drugs- Prostaglandins- Sex hormones and related drugs- Iodine and drugs that affect thyroid function- Insulin and other hypoglycemic drugs- Other hormones and related drugs- Lipid-regulated drugs- Endocrine and metabolic adverse effects of non-hormonal and non-metabolic drugs
Front Cover 1
Meyler's Side Effects of Endocrine and Metabolic Drugs 4
Copyright Page 5
Table of Contents 6
Preface 8
Section 1 Corticosteroids and related drugs 12
Chapter 1 Corticorelin (corticotropin-releasing hormone (CRH)) 14
General Information 14
References 14
Chapter 2 Corticosteroids—glucocorticoids 14
General Information 14
Organs and Systems 17
Long-Term Effects 50
Second-Generation Effects 52
Susceptibility Factors 56
Drug Administration 57
Drug–Drug Interactions 64
Diagnosis of adverse drug reactions 65
Management of adverse drug reactions 66
References 66
Chapter 3 Corticosteroids—glucocorticoids, inhaled 81
General Information 81
Organs and Systems 84
Second-Generation Effects 98
Drug–Drug Interactions 98
References 99
Chapter 4 Corticosteroids—glucocorticoids, topical 104
References 104
Chapter 5 Corticosteroids—mineralocorticoids 105
General Information 105
Organs and Systems 105
Drug–Drug Interactions 105
References 105
Chapter 6 Corticotrophins (corticotropin and tetracosactide) 106
General Information 106
Organs and Systems 106
Long-Term Effects 108
Second-Generation Effects 108
Susceptibility Factors 109
Drug–Drug Interactions 109
References 109
Section 2 Prostaglandins 112
General Information 114
Organs and Systems 118
Second-Generation Effects 118
Susceptibility Factors 118
Drug Administration 119
References 120
Chapter 7 Alprostadil 123
General Information 123
Organs and Systems 123
References 126
Chapter 8 Beraprost 127
General Information 127
Reference 127
Chapter 9 Bimatoprost 127
General Information 127
Organs and Systems 127
References 127
Chapter 10 Carboprost 127
General Information 127
Organs and Systems 127
Drug Administration 127
References 128
Chapter 11 Dinoprostone 128
General Information 128
Organs and Systems 128
Reference 128
Chapter 12 Enprostil 128
General Information 128
Organs and Systems 128
Reference 128
Chapter 13 Epoprostenol 128
General Information 128
Organs and Systems 129
Drug-drug interactions 130
Management of adverse drug reactions 130
References 130
Chapter 14 Gemeprost 131
General Information 131
Organs and Systems 131
References 131
Chapter 15 Iloprost 131
General Information 131
Organs and Systems 132
Drug Administration 133
References 133
Chapter 16 Latanoprost 133
General Information 133
Organs and Systems 133
Second-Generation Effects 137
Drug-drug interactions 137
References 137
Chapter 17 Misoprostol 138
General Information 138
Organs and Systems 140
Second-Generation Effects 140
Drug Administration 142
References 142
Chapter 18 Sulprostone 144
General Information 144
Organs and Systems 144
References 145
Chapter 19 Travoprost 145
General Information 145
Organs and Systems 145
References 145
Chapter 20 Unoprostone 145
General Information 145
Organs and Systems 145
Reference 145
Section 3 Sex hormones and related drugs 146
Chapter 21 Androgens and anabolic steroids 148
General Information 148
Organs and Systems 150
Long-Term Effects 153
Second-Generation Effects 155
Susceptibility Factors 155
Drug Administration 156
Drug–Drug Interactions 157
References 157
Chapter 22 Antiandrogens 160
General Information 160
Organs and Systems 163
Long-Term Effects 166
Susceptibility factors 166
Drug Administration 166
Drug-drug interactions 167
Interference with diagnostic routines 167
References 167
Chapter 23 Aromatase inhibitors 170
General Information 170
Organs and Systems 170
Long-Term Effects 171
Susceptibility Factors 172
Drug-Drug Interactions 172
References 172
Chapter 24 Chlorotrianisene 173
General Information 173
Organs and Systems 174
References 174
Chapter 25 Clomiphene 174
General Information 174
Organs and Systems 174
Long-Term Effects 174
Second-Generation Effects 175
References 175
Chapter 26 Cyclofenil 176
General Information 176
Organs and Systems 176
References 176
Chapter 27 Danazol 176
General Information 176
Organs and Systems 176
References 177
Chapter 28 Diethylstilbestrol 177
General Information 177
Organs and Systems 177
Long-Term Effects 178
Second-Generation Effects 178
Drug Administration 182
References 182
Chapter 29 Estrogens 183
General Information 183
Organs and Systems 185
Long-Term Effects 189
Second-Generation Effects 201
Susceptibility Factors 201
Drug Administration 202
References 204
Chapter 30 Gonadotropins 211
General Information 211
Organs and Systems 212
Long-Term Effects 214
Second-Generation Effects 216
Drug Administration 216
References 217
Chapter 31 Hormonal contraceptives—emergency contraception 219
General Information 219
Organs and Systems 221
Second-Generation Effects 221
Susceptibility Factors 221
References 221
Chapter 32 Hormonal contraceptives—intracervical and intravaginal 222
General Information 222
References 222
Chapter 33 Hormonal contraceptives—male 223
General Information 223
Organs and Systems 223
References 223
Chapter 34 Hormonal contraceptives—oral 224
General Information 224
Organs and Systems 226
Long-Term Effects 246
Second-Generation Effects 247
Susceptibility Factors 248
Drug Administration 249
Drug–Drug Interactions 250
Smoking 253
References 253
Chapter 35 Hormonal contraceptives—progestogen injections 263
General Information 263
References 264
Chapter 36 Hormonal contraceptives—progestogen implants 264
General Information 264
Organs and Systems 267
Second-Generation Effects 268
Drug Administration 268
References 269
Chapter 37 Hormonal contraceptives—transdermal 270
Reference 270
Chapter 38 Hormone replacement therapy—estrogens 270
General Information 270
Organs and Systems 272
Long-Term Effects 277
Susceptibility Factors 277
Drug Administration 278
Drug–Drug Interactions 280
Food-Drug Interactions 281
References 281
Chapter 39 Hormonal replacement therapy—estrogens + androgens 284
General Information 284
References 285
Chapter 40 Hormone replacement therapy—estrogens + progestogens 285
General Information 285
Organs and Systems 287
Long-Term Effects 289
Susceptibility Factors 289
Drug Administration 290
Drug–Drug Interactions 290
References 290
Chapter 41 Medroxyprogesterone 292
General Information 292
Organs and Systems 292
Long-Term Effects 294
Second-Generation Effects 294
Susceptibility Factors 294
Drug Administration 294
References 295
Chapter 42 Mifepristone 296
General Information 296
Organs and Systems 297
Long-Term Effects 298
Second-Generation Effects 298
Drug Administration 298
References 298
Chapter 43 Progestogens 299
General Information 299
Organs and Systems 301
Long-Term Effects 303
Second-Generation Effects 303
Drug Administration 304
Drug-drug interactions 306
References 306
Chapter 44 Raloxifene 308
General Information 308
Organs and Systems 309
Susceptibility factors 310
Drug–Drug Interactions 310
References 310
Chapter 45 Tamoxifen 312
General Information 312
Organs and Systems 314
Long-Term Effects 318
Second-Generation Effects 320
Susceptibility Factors 320
Drug–Drug Interactions 320
Drug–Procedure Interactions 320
Management of adverse drug reactions 321
References 321
Chapter 46 Tibolone 325
General Information 325
Organ and Systems 325
Drug-drug interactions 325
References 325
Section 4 Iodine and drugs that affect thyroid function 326
Chapter 47 Iodine-containing medicaments 328
General Information 328
Organs and Systems 330
Second-Generation Effects 332
Drug Administration 332
Interference with Diagnostic Tests 333
References 333
Chapter 48 Iodine radioactive 335
General Information 335
Organs and Systems 335
Long-Term Effects 336
Second-Generation Effects 337
Interference with Diagnostic Tests 338
References 338
Chapter 49 Polyvidone and povidone-iodine 339
General Information 339
Organs and Systems 340
Second-Generation Effects 342
Susceptibility Factors 342
Drug Administration 343
Interference with Diagnostic tests 343
References 343
Chapter 50 Potassium perchlorate 345
General Information 345
Organs and Systems 345
References 345
Chapter 51 Protirelin 345
General Information 345
Organs and Systems 345
References 346
Chapter 52 Thionamides 346
General Information 346
Organs and Systems 347
Second-Generation Effects 351
Susceptibility Factors 353
Drug Administration 353
Drug–Drug Interactions 353
References 353
Chapter 53 Thyroid hormones 357
General Information 357
Organs and Systems 358
Long-Term Effects 361
Second-Generation Effects 361
Susceptibility Factors 361
Drug Administration 362
Drug–Drug Interactions 362
Monitoring Therapy 363
References 364
Chapter 54 Thyrotrophin and thyrotropin 366
General Information 366
Organs and Systems 366
References 366
Section 5 Insulins and other hypoglycemic drugs 368
Chapter 55 Aldose reductase inhibitors 370
General Information 370
Organs and Systems 370
References 370
Chapter 56 Alpha-glucosidase inhibitors 370
General Information 370
Organs and Systems 371
Second-Generation Effects 374
Drug–Drug Interactions 374
References 375
Chapter 57 Amylin analogues 377
General Information 377
Organs and Systems 378
Drug-drug interactions 378
References 378
Chapter 58 Biguanides 378
General Information 378
Organs and Systems 381
Second-Generation Effects 386
Susceptibility Factors 387
Drug Administration 387
Drug–Drug Interactions 388
References 389
Chapter 59 Blood glucose meters 393
General Information 393
Organs and Systems 394
References 394
Chapter 60 Dipeptidyl peptidase IV inhibitors 394
General information 394
Organs and Systems 395
Drug-drug interactions 395
References 395
Chapter 61 Glucagon 395
General Information 395
Organs and Systems 396
Susceptibility Factors 396
References 397
Chapter 62 Glucagon-like peptide-1 397
General Information 397
Organs and Systems 397
References 398
Chapter 63 Guar gum 398
General Information 398
Organs and Systems 398
References 398
Chapter 64 Incretin mimetics 399
General Information 399
Organs and Systems 399
Long-Term Effects 400
Drug administration 401
Drug-Drug Interactions 401
References 401
Chapter 65 Insulin 402
General Information 402
Organs and Systems 404
Long-Term Effects 414
Second-Generation Effects 414
Susceptibility Factors 415
Drug Administration 415
Drug–Drug Interactions 422
Interference with Diagnostic Tests 423
Management of adverse drug reactions 424
Monitoring Therapy 424
References 424
Chapter 65 Insulin aspart 433
General Information 433
Organs and Systems 434
References 434
Chapter 66 Insulin detemir 435
General Information 435
Organs and Systems 436
References 436
Chapter 67 Insulin glargine 436
General Information 436
Organs and Systems 437
Drug Administration 438
References 438
Chapter 68 Insulin lispro 439
General Information 439
Organs and Systems 440
Second-Generation Effects 442
Susceptibility Factors 442
Drug Administration 442
References 442
Chapter 69 Insulin-like growth factor (IGF-I) 444
General Information 444
Organs and Systems 444
Long-Term Effects 445
References 445
Chapter 70 Meglitinides 445
General Information 445
Organs and Systems 448
Susceptibility Factors 449
Drug–Drug Interactions 449
References 450
Chapter 71 Sulfonylureas 452
General Information 452
Organs and Systems 454
Second-Generation Effects 459
Susceptibility Factors 460
Drug Administration 460
Drug–Drug Interactions 462
Management of adverse drug reactions 464
References 464
Chapter 72 Thiazolidinediones 469
General Information 469
Organs and Systems 472
Susceptibility Factors 479
Drug–Drug Interactions 479
References 480
Section 6 Other hormones and related drugs 486
Chapter 73 Calcitonin 488
General Information 488
Organs and Systems 488
Drug Administration 489
Drug–Drug Interactions 489
References 489
Chapter 74 Desmopressin 490
General Information 490
Organs and Systems 491
Second-Generation Effects 494
Susceptibility factors 494
Drug–Drug Interactions 494
References 495
Chapter 75 Follitropin 497
General Information 497
Organs and Systems 497
References 497
Chapter 76 Gonadorelin and analogues 497
General Information 497
Organs and Systems 498
Long-Term Effects 501
Second-Generation Effects 502
Drug Administration 502
Drug-Drug Interactions 502
Management of adverse drug reactions 502
References 502
Chapter 77 Gonadorelin antagonists 505
General Information 505
Organs and Systems 505
References 505
Chapter 78 Melatonin 506
General Information 506
Organs and Systems 506
Long-Term Effects 508
Drug Administration 508
Drug–Drug Interactions 508
References 509
Chapter 79 Oxytocin and analogues 509
General Information 509
Organs and Systems 510
Second-Generation Effects 510
References 511
Chapter 80 Parathyroid hormone and analogues 511
General Information 511
Organs and Systems 511
Long-Term Effects 512
Drug–Drug Interactions 512
References 512
Chapter 81 Somatostatin and analogues 513
General Information 513
Organs and Systems 514
Second-Generation Effects 516
Susceptibility Factors 517
Drug–Drug Interactions 517
References 517
Chapter 82 Somatropin (growth hormone) 519
General Information 519
Organs and Systems 519
Long-Term Effects 524
Second-Generation Effects 525
Susceptibility Factors 525
Drug Administration 525
Drug–Drug Interactions 526
References 526
Chapter 83 Somatropin (growth hormone) receptor antagonists 530
General Information 530
Organs and Systems 530
Long-Term Effects 531
References 531
Chapter 84 Vasopressin and analogues 531
General Information 531
Organs and Systems 532
Drug Administration 533
References 534
Chapter 85 Vasopressin receptor antagonists 535
General Information 535
Organs and Systems 535
Drug-Drug Interactions 535
References 535
Section 7 Lipid – regulating drugs 538
Chapter 86 Acipimox 540
General Information 540
Organs and Systems 540
References 540
Chapter 87 Atorvastatin 540
General Information 540
Organs and Systems 540
Drug Administration 541
Drug–Drug Interactions 542
References 542
Chapter 88 Cerivastatin 543
General Information 543
Organs and Systems 544
Drug–Drug Interactions 544
References 544
Chapter 89 Ezetimibe 545
General Information 545
Organs and Systems 545
Drug-drug interactions 545
References 545
Chapter 90 Fibrates 546
General Information 546
Organs and Systems 546
Long-Term Effects 548
Second-Generation Effects 548
Drug–Drug Interactions 548
References 550
Chapter 91 Fish oils 552
General Information 552
Organs and Systems 552
Second-Generation Effects 553
Drug–Drug Interactions 553
References 553
Chapter 92 Fluvastatin 554
General Information 554
Organs and Systems 554
Drug Administration 555
Drug–Drug Interactions 555
References 555
Chapter 93 HMG coenzyme-A reductase inhibitors 555
General Information 555
Organs and Systems 556
Long-Term Effects 560
Drug–Drug Interactions 560
References 563
Chapter 94 Ion exchange resins 566
General Information 566
Organs and Systems 566
Drug–Drug Interactions 567
References 568
Chapter 95 Lorenzo's oil 568
General Information 568
Organs and Systems 569
References 569
Chapter 96 Lovastatin 569
General Information 569
Organs and Systems 569
Drug–Drug Interactions 569
References 570
Chapter 97 Nicotinic acid and derivatives 571
General Information 571
Organs and Systems 572
Drug Administration 574
Drug-Drug Interactions 574
References 575
Chapter 98 Pravastatin 576
General Information 576
Organs and Systems 576
Drug–Drug Interactions 576
References 577
Chapter 99 Probucol 577
General Information 577
Organs and Systems 577
References 577
Chapter 100 Simvastatin 577
General Information 577
Organs and Systems 578
Second-Generation Effects 579
Drug–Drug Interactions 579
References 580
Section 8 Endocrine and metabolic adverse effects of non-hormonal and non-metabolic drugs 582
Abacavir 584
Acetylsalicylic acid 584
Adrenaline 584
Albumin 584
Aldesleukin 584
Alemtuzumab 585
Alprazolam 585
Aminoglycoside antibiotics 585
Amiodarone 585
Amisulpride 589
Amoxapine 590
Amphetamines 590
Angiotensin-converting enzyme inhibitors 590
Antacids 590
Antiepileptic drugs 590
Antihistamines 593
Antiretroviral drugs 593
Apiaceae 595
Aripiprazole 595
Artesunate 596
Articaine 596
Ascorbic acid (vitamin C) 596
Asparaginase 596
Azathioprine 596
Benazepril 596
Benzodiazepines 597
Beta2-adrenoceptor agonists 597
Beta-adrenoceptor antagonists 597
Beta-lactam antibiotics 598
Bile acids 599
Bisoprolol 599
Bisphosphonates 599
Bromocriptine 599
Bumetanide 599
Caffeine 599
Calcipotriol 599
Calcium channel blockers 599
Cannabinoids 600
Carbamazepine 600
Carbenoxolone 600
Carbonic anhydrase inhibitors 600
Cardiac glycosides 601
Carvedilol 602
Ceftriaxone 602
Celastraceae 602
Chlordiazepoxide 602
Chloroquine and hydroxychloroquine 602
Cibenzoline 603
Ciclosporin 603
Cimetidine 604
Citric acid and citrates 604
Clomipramine 604
Clonazepam 605
Clonidine and apraclonidine 605
Clozapine 605
Clusiaceae 606
Cocaine 606
Colchicine 607
Complementary and alternative medicine 607
Coumarin anticoagulants 607
Cucurbitaceae 607
Cyclophosphamide 607
Cytostatic and immunosuppressant drugs 608
Dexamfetamine 608
Dextromethorphan 608
Dextropropoxyphene 608
Diamorphine 608
Diazepam 608
Diazoxide 608
Disopyramide 609
Diuretics 609
Donepezil 611
Doxycycline 611
Efavirenz 611
Enalapril 611
Encainide 611
Enflurane 611
Ephedra, ephedrine, and pseudoephedrine 612
Erythropoietin, epoetin alfa, epoetin beta, epoetin gamma, and darbepoetin 612
Etacrynic acid 612
Etanercept 612
Ethambutol 612
Ethionamide and protionamide 612
Etomidate 612
Everolimus 612
Fenfluramine 612
Fentanyl 612
Fluconazole 613
Flumazenil 613
Fluoroquinolones 613
Fluorouracil 613
Fluoxetine 613
Flutamide 613
Fluvoxamine 614
Fructose and sorbitol 614
Furosemide 614
Gabapentin 614
Ganciclovir 614
Gatifloxacin 614
General anesthetics 615
Glycerol 615
Glycyrrhiza species (Fabaceae) 615
Glycols 615
Gold and gold salts 615
Granulocyte colony-stimulating factor (G-CSF) 615
Granulocyte–macrophage colony-stimulating factor (GM-CSF) 615
Griseofulvin 616
Haemophilus influenzae type b (Hib) vaccine 616
Halogenated quinolines 616
Haloperidol 616
Heparins 617
Hydralazine 617
Ibuprofen 617
Imipenem 617
Immunoglobulins 617
Indapamide 617
Indinavir 617
Indometacin 618
Infliximab 618
Interferon alfa 618
Interferon beta 622
Interferon gamma 623
Interleukin-1 623
Interleukin-4 623
Interleukin-6 623
Iodinated contrast media 623
Iron salts 624
Isoniazid 625
Ketamine 625
Ketoconazole 625
Lamotrigine 625
Leflunomide 625
Levodopa and dopa decarboxylase inhibitors 625
Levofloxacin 626
Lidocaine 626
Linezolid 626
Lisinopril 626
Lithium 626
Local anesthetics 631
Lopinavir + ritonavir 632
Lorazepam 632
Lorcainide 632
Manganese 632
Maprotiline 632
Measles, mumps, and rubella vaccines 632
Mefloquine 632
Methadone 632
Methyldopa 632
Methylphenidate 633
Metoclopramide 633
Metronidazole 633
Miconazole 633
Minocycline 633
Minoxidil 633
Mitotane 633
Mizoribine 633
Moclobemide 634
Monoamine oxidase inhibitors 634
Morphine 634
Moxifloxacin 634
Nalidixic acid 634
Naloxone 634
Nabumetone 634
Nefazodone 634
Nelfinavir 634
Neuroleptic drugs 635
Nevirapine 641
Nicorandil 641
Nicotinic acid and derivatives 641
Nitrofurantoin 641
Nucleoside analogue reverse transcriptase inhibitors (NRTIs) 641
Ofloxacin 642
Olanzapine 642
Omeprazole 645
Opioid analgesics 645
Oxaprozin 646
Pancreatic enzymes 646
Pantothenic acid derivatives 646
Paracetamol 646
Parenteral nutrition 646
Paroxetine 648
Penicillamine 648
Penicillins 648
Pentamidine 649
Phenylbutazone 649
Phenytoin and fosphenytoin 649
Phosphates 649
Photochemotherapy (PUVA) 649
Pizotifen 649
Platinum-containing cytostatic drugs 649
Prazosin 650
Propafenone 650
Propofol 650
Protease inhibitors 652
Pyrazinamide 653
Pyritinol 653
Quetiapine 653
Quinine 654
Ramipril 654
Reboxetine 654
Reserpine 654
Rifamycins 654
Risperidone 655
Ritodrine 657
Roxithromycin 657
Salbutamol 657
Saquinavir 658
Selective serotonin re-uptake inhibitors (SSRIs) 658
Selenium 658
Sertindole 658
Sertraline 658
Sirolimus 658
Smallpox vaccine 659
Sorafenib 659
Spironolactone 659
Stavudine 659
Sulfonamides 659
Sunitinib 659
Suramin 660
Tacrolimus 660
Tenofovir 661
Terbutaline 661
Tetracyclines 661
Thalidomide 662
Theophylline 662
Thiazide diuretics 662
Thiopental sodium 662
Tiabendazole 663
Tiagabine 663
Tiopronin 663
Topiramate 663
Tricyclic antidepressants 663
Trimethoprim and co-trimoxazole 664
Tripterygium wilfordii (Celastraceae) 664
Troleandomycin 664
Tumor necrosis factor alfa 664
Valproic acid 664
Vancomycin 667
Verapamil 667
Vigabatrin 667
Vinca alkaloids 667
Vitamin A: Carotenoids 667
Vitamin A: Retinoids 667
Vitamin D analogues 668
Xipamide 668
Zidovudine 668
Ziprasidone 668
Zopiclone 668
References 668
Index of drug names 704
| Erscheint lt. Verlag | 21.2.2009 |
|---|---|
| Sprache | englisch |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
| Naturwissenschaften ► Chemie | |
| Technik | |
| ISBN-10 | 0-08-093292-4 / 0080932924 |
| ISBN-13 | 978-0-08-093292-7 / 9780080932927 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
